Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
Delayed Nasdaq  -  04:00 2022-09-27 pm EDT
8.480 USD   +3.41%
09/20Protagonist Therapeutics Reports Granting of Inducement Award
PR
08/25JMP Securities Reinstates Protagonist Therapeutics at Market Outperform With $21 Price Target
MT
08/04Protagonist Therapeutics : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Protagonist Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

08/04/2022 | 04:59pm EDT

Protagonist Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 41.04 million compared to USD 30.84 million a year ago. Basic loss per share from continuing operations was USD 0.84 compared to USD 0.69 a year ago.
For the six months, net loss was USD 61.97 million compared to USD 54.84 million a year ago. Basic loss per share from continuing operations was USD 1.27 compared to USD 1.23 a year ago.


© S&P Capital IQ 2022
All news about PROTAGONIST THERAPEUTICS, INC.
09/20Protagonist Therapeutics Reports Granting of Inducement Award
PR
08/25JMP Securities Reinstates Protagonist Therapeutics at Market Outperform With $21 Price ..
MT
08/04Protagonist Therapeutics : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
08/04Protagonist Therapeutics : Q2 Earnings Snapshot
AQ
08/04PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
08/04Protagonist Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six ..
CI
08/04Protagonist Therapeutics : Reports Second Quarter 2022 Financial Results and Provides Corp..
PU
07/19Protagonist Therapeutics Reports Granting of Inducement Award
PR
06/24Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added..
CI
06/24Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropp..
CI
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 32,8 M - -
Net income 2022 -142 M - -
Net cash 2022 206 M - -
P/E ratio 2022 -2,97x
Yield 2022 -
Capitalization 416 M 416 M -
EV / Sales 2022 6,41x
EV / Sales 2023 27,8x
Nbr of Employees 127
Free-Float 98,6%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 8,48 $
Average target price 37,29 $
Spread / Average Target 340%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Asif Ali Chief Financial Officer & Executive Vice President
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Research & Development Strategy Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.-75.20%402
MODERNA, INC.-51.87%46 823
IQVIA HOLDINGS INC.-35.18%34 705
LONZA GROUP AG-42.20%32 942
SEAGEN INC.-12.45%24 949
ALNYLAM PHARMACEUTICALS, INC.16.40%23 692